1. Home
  2. TTEC vs INAB Comparison

TTEC vs INAB Comparison

Compare TTEC & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TTEC Holdings Inc.

TTEC

TTEC Holdings Inc.

HOLD

Current Price

$1.24

Market Cap

67.0M

Sector

Technology

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.16

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TTEC
INAB
Founded
1982
2016
Country
United States
United States
Employees
69400
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.0M
11.8M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
TTEC
INAB
Price
$1.24
$1.16
Analyst Decision
Hold
Strong Buy
Analyst Count
2
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
341.8K
32.8K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
40.80
N/A
EPS
N/A
N/A
Revenue
$1,509,171,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.10
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.15
N/A
52 Week Low
$1.18
$0.88
52 Week High
$3.99
$2.73

Technical Indicators

Market Signals
Indicator
TTEC
INAB
Relative Strength Index (RSI) 30.39 N/A
Support Level N/A N/A
Resistance Level $2.49 N/A
Average True Range (ATR) 0.06 0.00
MACD 0.02 0.00
Stochastic Oscillator 17.39 0.00

Price Performance

Historical Comparison
TTEC
INAB

About TTEC TTEC Holdings Inc.

TTEC Holdings Inc provides customer engagement management tools and services. The company operates through two operating segment, TTEC Digital and TTEC Engage. TTEC Digital is engaged in building and implementing cloud-based and on-premises customer experience tools that enable clients to develop customer engagement strategies. TTEC Engage focuses on delivering sales and marketing solutions to help clients boost their revenue as well as on managing customer's front-to-back office processes to optimize the customer experience. TTEC Engage contributes the vast majority of the company's revenue, and its revenues are derived from the United States and Canada, followed by Philippines, Asia-Pacific and India.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: